Connect with us

Biotech

Clinicas Mi Strengthens its Position and Increases Capital by Half a Million Euros

Clinicas Mi is a group of clinics of Catalan origin, owned by the Masfurroll family, a surname with a long tradition in Spanish healthcare. At the end of 2014, the Masfurroll family acquired Clínica Tres Torres in Barcelona along with its team, currently controlling more than 95% of the capital. The group has this center and Clínica Mi NovAliança in Lleida.

Published

on

Clínicas Mi rebalances its financial situation after the impact of Covid-19. The private Catalan healthcare group has increased capital by half a million euros, as confirmed by Gaby Masfuroll, CEO of the company.

The capital increase has been subscribed by the current partners of the healthcare group. The aim of the operation, beyond compensating for the effect of the pandemic, is to “strengthen the company with a view to its plans for growth, technological innovation and the incorporation of new professionals,” said Masfuroll.

The shareholders will meet at the end of September to approve the capital injection. “The action should enable us to guarantee the company’s solidity and restructure the group,” he added.

Read more on the subject and find other important business headlines with the Born2Invest mobile app

Clinicas Mi will hold a shareholders’ meeting at the end of September to validate this capital increase

Clinicas Mi is a group of clinics of Catalan origin, owned by the Masfurroll family, a surname with a long tradition in Spanish healthcare. At the end of 2014, the Masfurroll family acquired Clínica Tres Torres in Barcelona along with its team, currently controlling more than 95% of the capital. The group has this center and Clínica Mi NovAliança in Lleida.

In the latter facility, the company has made an investment of two million euros. The investment is for the refurbishment of the outpatients’ building at this center in Lleida. It consists of 2,000 square meters of space. The company put this clinic into operation in June 2020, after months of confinement and following the declaration of the state of alarm in Spain.

SEE ALSO  Cambodia’s leopards are on the brink of extinction

The group took over the management of this historic clinic in Lleida, previously known as Clínica de Ponent and Clínica Aliança, in September 2016. At the time of taking over management, Clinicas Mi and Divina Pastora, owner of the facility since 2013, agreed on a possible right to purchase the business, which was finally exercised in the first half of 2020.

The group has two centers, Clinica Tres Torres in Barcelona and Clinica Mi NovAliança in Lleida

The management team leading the clinics in Barcelona and Lleida brings experience, backed by historic projects in the sector such as the creation in 1998 of USP Hospitales, the first private hospital network in southern Europe.

Among the latest operations of Cínicas Mi is the incorporation of the Ginnova team as new specialists in the area of gynecology and obstetrics at its Barcelona campus. The professionals of this new project, who have been working together for more than twenty years, are led by Pere Brescó. This doctor is also head of the gynecological area of the Igualada Hospital.

__

(Featured image by TheShiv76 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.

Continue Reading